-
Valeant Falls Following Report Of SEC Investigation That Was Already Announced
Wednesday, March 1, 2017 - 5:25pm | 251Read More..."Fake news" strikes again — and this time spooks Valeant Pharmaceuticals Intl Inc (NYSE: VRX) investors. Shares fell 5 percent Wednesday afternoon following a Reuters report "announcing" the SEC’s investigation of Salix for possible securities law violations. However...
-
Citron Compares Express Scripts To Philidor: 'Culprit Behind Pharmaceutical Price Gouging'
Thursday, December 8, 2016 - 2:40pm | 268Read More...The culprit behind price gouging? In tweets sent out Thursday directed at President-elect Donald Trump, Citron Research targeted pharmacy benefit giant Express Scripts Holding Company (NASDAQ: ESRX), referring to the company as "the Philidor of the pharma industry," and setting a $45...
-
An Update On The Ackman Trades
Wednesday, November 9, 2016 - 2:19pm | 505Read More...Pershing Square Holding, the hedge fund controlled by billionaire Bill Ackman, once more brought home a bad report card. Monthly portfolio update issued by the company for October showed that net performance of the fund was down 22.5 percent in the year-to-date period. This is despite the broader...
-
Pot, Meet Kettle: Wells Fargo Says Valeant's Stock Too Risky In Light Of Potential Fraud Charges
Tuesday, November 1, 2016 - 11:48am | 411Read More...Wells Fargo reiterated its Underperform rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), saying the new Bloomberg report over potential accounting fraud charges on the company makes the stock further risky for investment. Bloomberg reported that U.S. authorities are investigating potential...
-
Valeant Takes Another Hit Following Potential Fraud Investigation
Tuesday, November 1, 2016 - 7:22am | 322Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plummeted more than 12 percent Monday afternoon and hit a new 52-week low of $17.75 following a Bloomberg report that U.S. prosecutors are focusing on the company's ex-CEO and ex-CFO. Bloomberg reported shortly before Monday's market close...
-
Valeant Being Sued In NY Federal Court Over Alleged Overcharges
Monday, August 29, 2016 - 3:53pm | 154Read More...Buyers of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) drugs sued the company on Monday, claiming that they had been forced to pay excessive prices due to the company’s relation to Philidor Rx Services. According to the complaint, the Pennsylvania-licensed specialty online pharmacy helped...
-
One Year Later: Valeant's 90% Fall From Grace
Thursday, August 11, 2016 - 6:43am | 925Read More...One of the most incredible market stories of the last year has been the absolute implosion of Valeant Pharmaceuticals Intl Inc (NYSE: VRX). In the not too distant past, Valeant was one of the top performing stocks in the entire market, and certainly for its size. In mid-2012, shares were trading...
-
JPMorgan Isn't Concerned About Valeant's Ad Hoc Committee At All; Says Sum-Of-The-Parts Shows Upside
Tuesday, April 5, 2016 - 11:57am | 317Read More...Despite the plethora of bad press lately, it's not all bad news for Valeant Pharmaceuticals Intl Inc (NYSE: VRX). On Tuesday morning, the biopharmaceutical company announced that its Ad Hoc Committee, which has been engaged in reviewing the Philidor matter in addition to other accounting concerns,...
-
Valeant Shares Squeezed Higher As Ad Hoc Committee Closes Review, Finds No Added Issues
Tuesday, April 5, 2016 - 10:15am | 269Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading higher by more than 9 percent after Tuesday's market open. Valeant announced that an ad hoc committee of the board of directors concluded its review of various Philidor and related account matters. The committee stated it...
-
Former Valeant CFO: I Did Not Engage In Improper Conduct
Monday, March 21, 2016 - 11:20am | 400Read More...On the back of news from Valeant Pharmaceuticals Intl Inc (NYSE: VRX) regarding changes to its board of directors, former CFO Howard Schiller has defended his decision to not step down from the board. In a Monday press release, the company outlined upcoming changes, including the voluntary...
-
Valeant Announces CEO Succession Plans And Financial Update; Bill Ackman Joins Board
Monday, March 21, 2016 - 9:52am | 715Read More...Amid a sinking stock price and a flurry of downgrades, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has released some progressive news In a press release, Valeant announced a search for a new CEO, Bill Ackman as a new member of the board and other internal matters such as the 10-K filing delay...
-
Valeant Just Received 2 More Downgrades
Monday, March 21, 2016 - 9:14am | 438Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is down 73 percent year-to-date. It should come as little surprise, therefore, that the stock is seeing its share of downgrades for 2016. Joining the party on Monday are Barclays and Mizuho Securities. Barclays: Downgrade To Equal-Weight, $34 PT...
-
Long-Time Valeant Bull Jefferies Cuts Price Target 40%
Tuesday, March 1, 2016 - 10:27am | 278Read More...Jefferies' David Steinberg maintained a Buy rating on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), while lowering the price target from $172 to $106. Steinberg mentioned that CEO Mike Pearson had returned to his position following a severe bout of pneumonia. At the same time, the company withdrew...
-
A Visual Look At Valeant's Dark Monday
Tuesday, February 23, 2016 - 7:30am | 290Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) started the week lower with a 10.7 percent decline in Monday's regular session and 7 percent decline after hours. The selloff was driven by several catalysts. Premarket Shares gained almost 2 percent in the premarket following...
-
Valeant Gets Closer To Left's $50 Target After New Accounting Fears
Monday, February 22, 2016 - 9:59pm | 379Read More...Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) shares plunged nearly 9 percent in Monday's after-hours trading session following word the company may have to restate financial results, before recovering slightly. The potential restatement, according to sources, would come on the heels of a...
